Usefulness of quantitative assessment of wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy

Seminars in Hematology

Volumn 40, Issue 2 SUPPL. 2, 2003, Pages 37-41

  Cilloni, Daniela ^a   Saglio, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; WT1 PROTEIN; BIOLOGICAL MARKER; MESSENGER RNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOGENETICS; DRUG RESPONSE; GENE EXPRESSION; HUMAN; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR SUPPRESSOR GENE; GENETICS; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RNA, MESSENGER; WT1 PROTEINS;

EID: 0037762627     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2003.50040     Document Type: Conference Paper

References (57)

1. Algar EM, Khromykh T, Smith SI, et al: A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene 12:1005-1014, 1996
2. Ault P, Cortes J, Koller C, et al: Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 9:881-884, 2002
3. Baird PM, Simmons PJ: Expression of the Wilms tumor gene (WT1) in normal hemopoiesis. Exp Hematol 25:312-320, 1997
4. Bove KE, McAdams AJ: The nephroblastomatosis complex and its relationship to Wilms tumor - A clinicopathological treatise. Prospect Pediatric Pathol 3:185-223, 1976
5. Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475, 2002
6. Call KM, Glaser T, Ito CY, et al: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520, 1990
7. Cilloni D, Gottardi E, De Micheli D, et al: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16:2115-2121, 2002
8. Cilloni D, Gottardi E, Messa F, et al: Very significant correlation between the degree of WT1 expression and the IPSS score in patients affected by myelodysplastic syndromes. J Clin Oncol (in press)
9. Cilloni D, Messa F, Gottardi E, et al: The quantitative assessment of WT1 as a method to predict response to STI571 in CML patients. Hematol J 3:176, 2002 (suppl 1, abstr)
10. Cook DM, Hinkes MT, Bernfield M, et al: Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene 13:1789-1799, 1996
11. Deuel TF, Guan LS, Wang ZY: Wilms' tumor gene product WT1 arrests macrophage differentiation of HL60 cells through its zinc-finger domain. Biochem Biophys Res Commun 254:192-196, 1999
12. Englert C, Hou X, Maheswaran S, et al: WT1 suppress synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 14:4662-4675, 1995
13. Fearon ER, Volgelstein B, Feinberg AP: Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumours. Nature 309:176-178, 1984
14. Gaiger A, Reese V, Disis ML, et al: Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96:1480-1489, 2000
15. Gaiger A, Schmid D, Heinze G, et al: Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 12:1886-1894, 1998
16. + leukemic cells to the ABL inhibitor STI571. J Natl Cancer Inst 92:1641-1650, 2000
17. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95:2198-2203, 2000
18. Gleich GJ, Leiferman KM, Pardanani A, et al: Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 359:1577-1578, 2002
19. Gorre ME, Sawyers CL: Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 9:303-307, 2002
20. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
21. Hawkins M, Draper G, Kingston J: Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 56:339-347, 1987
22. Hewitt SM, Hamada S, McDonnell TJ, et al: Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 55:5386-5389, 1995
23. Hoover RR, Mahon FX, Melo JV, et al: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100:1068-1071, 2002
24. Hosono S, Gross I, English MA, et al: E-Cadherin is a WT1 target gene. J Biol Chem 275:10943-10953, 2000
25. Inoue K, Ogawa H, Sonoda Y, et al: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405-1412, 1997
26. Inoue K, Tamaki H, Ogawa H, et al: Wilms' tumor gene (WT1) competes with differentiation inducing signal in hematopoietic progenitor cells. Blood 91:2969-2976, 1998
27. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
28. King-Underwood L, Renshaw J, Pritchard-Jones K: Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 87:2171-2179, 1996
29. Koufos A, Hansen MF, Lampkin BC, et al: Loss of alleles on human chromosome 11 during genesis of Wilms' tumor. Nature 309:170-172, 1984
30. Kreuzer KA, Saborowski A, Lupberger J, et al: Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: Implications for monitoring human leukemias. Br J Hematol 114:313-318, 2001
31. Lee SB, Huang K, Palmer R, et al: The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 98:663-673, 1999
32. Little M, Wells C: A clinical overview of WT1 gene mutations. Hum Mutat 9:209-225, 1997
33. Madden SL, Cook DM, Morris JF, et al: Transcriptional repression mediated by the WT1 Wilms' tumor gene product. Science 253:1550-1553, 1991
34. + progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 25:945-950, 1997
35. + progenitors. Blood 90:4230-4232, 1997
36. + hematopoietic progenitors during fetal development and early clonogenic growth. Blood 89:3486-3487, 1997
37. Menssen HD, Renkl HJ, Rieder H, et al: Distinction of eosinophilic leukemia from idiopathic hypereosinophilic syndrome by analysis of Wilms' tumour gene expression. Br J Hematol 101:325-334, 1998
38. Menssen HD, Renkl HJ, Rodeck U, et al: Presence of Wilms' tumor gene (WT1) transcripts and WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9:1060-1067, 1995
39. Menssen HD, Siehl JM, Thiel E: Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol 76:103-109, 2002
40. Miller RW, Fraumeni JF, Manning MD: Association of Wilms' tumor with aniridia, hemihypertrophy and other congenital anomalies. N Engl J Med. 270:922-927, 1964
41. Miwa H, Beran M, Saunders GF: Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6:405-409, 1992
42. Miyagawa K, Hayashi Y, Fukuda T, et al: Mutations of the WT1 gene in childhood non-lymphoid hematological malignancies. Genes Chromosomes Cancer 25:176-183, 1999
43. Nieborowska-Skorska M, Slupianek A, Skorski T: Progressive changes in the leukemogenic signaling in BCR/ABL transformed cells. Oncogene 19:4117-4124, 2000
44. Orkin SH, Golman DS, Sallan SE: Development of homozygosity for chromosome 11p markers in Wilms' tumour. Nature 309:172-174, 1984.
45. Park S, Schalling M, Bernard A, et al: The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 4:415-420, 1993
46. Pritchard-Jones K, Fleming S: Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumour: Implications for tumour histogenesis. Oncogene 6:2211-2220, 1991
47. Reeve AE, Housiaux PJ, Gardner RJM, et al: Loss of a Harvey ras allele in sporadic Wilms' tumour. Nature 309:174-176, 1984
48. Riccardi VM, Sujansky E, Smith AC, et al: Chromosomal imbalance in the aniridia-Wilms' tumor association: 11p interstitial deletion. Pediatrics 61:604-610, 1978
49. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al: Several types of mutations of the ABL gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014-1018, 2002
50. Sekiya M, Adachi M, Hinoda Y, et al: Downregulation of the Wilms' tumor gene (WT1) during myelomonocytic differentiation in HL60 cells. Blood 83:1876-1882, 1994
51. Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
52. Smith SI, Weil D, Johnson GR, et al: Expression of the Wilms' tumor suppressor gene, WT1 is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells. Blood 91:764-773, 1998
53. Svedberg H, Chylicki K, Baldetorp B, et al: Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks part of the differentiation program. Oncogene 16:925-932, 1998
54. Trka J, Kalinova M, Hrusak O, et al: Real time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16:1381-1389, 2002
55. Weisberg E, Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL transformed hematopoietic cell lines. Blood 95:3498-3505, 2000
56. Xavier Mahon F, Deininger MWN, Schultheis B, et al: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanism of resistance. Blood 96:1070-1079, 2000
57. Yamagami T, Sugiyama H, Inoue K, et al: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 87:2878-2884, 1996